Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Geratherm Medical AGXTER:GME -1.56%72 EV-to-EBITDA is 19.64 as of Aug. 20, 2026, which is 56% above its 10-year median of 12.61. GuruFocus rates XTER:GME with a GF Score™ of 72/100 and a GF Value™ of €3.13 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 515 Medical Devices & Instruments companies, Geratherm Medical AG ranks worse than 64.08% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Geratherm Medical AG's enterprise value is €6.70 Mil.
Geratherm Medical AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €0.34 Mil. Therefore, Geratherm Medical AG's EV-to-EBITDA for today is 19.64.
The historical rank and industry rank for Geratherm Medical AG's EV-to-EBITDA or its related term are showing as below:
XTER:GME'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.86 Med: 12.61 Max: 26.14
Current: 19.95
During the past 13 years, the highest EV-to-EBITDA of Geratherm Medical AG was 26.14. The lowest was -7.86. And the median was 12.61.
XTER:GME's EV-to-EBITDA is ranked worse than 64.08% of 515
companies
in the Medical Devices & Instruments industry
Industry Median: 15.16
vs XTER:GME: 19.95
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Geratherm Medical AG (XTER:GME) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Geratherm Medical AG's PE Ratio (TTM) for today is calculated as:
Geratherm Medical AG's share price for today is €2.53.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Geratherm Medical AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.157.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Geratherm Medical AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:GME vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Geratherm Medical AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Geratherm Medical AG EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Geratherm Medical AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Geratherm Medical AG's EV-to-EBITDA falls into.
Geratherm Medical AG's current Enterprise Value is €6.70 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Geratherm Medical AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €0.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Geratherm Medical AG (XTER:GME) has a EV-to-EBITDA of 19.64 as of Aug. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Geratherm Medical AG. This is 56% above median its historical median of 12.61. According to the industry distribution chart, Geratherm Medical AG ranks #330 out of 515 companies in the Medical Devices & Instruments industry, placing it in the top 64.1%.
Is Geratherm Medical AG's EV-to-EBITDA too high?
Geratherm Medical AG's current EV-to-EBITDA of 19.64 is 56% above median its 10-year median of 12.61. The Medical Devices & Instruments industry median EV-to-EBITDA is 15.16. Geratherm Medical AG's value of 19.64 is 29.6% above this industry median. Based on the distribution chart, Geratherm Medical AG ranks #330 out of 515 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Geratherm Medical AG has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Geratherm Medical AG's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Geratherm Medical AG ranks #330 out of 515 companies for EV-to-EBITDA. This places Geratherm Medical AG in the lower half of its industry. The industry median EV-to-EBITDA is 15.16. Geratherm Medical AG's value of 19.64 is 29.6% above this benchmark. While the company's 10-year median is 12.61 vs. the industry median of 15.16, Geratherm Medical AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 15.16, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Geratherm Medical AG's current EV-to-EBITDA of 19.64 is 29.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Geratherm Medical AG. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 15.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Geratherm Medical AG's current EV-to-EBITDA is 19.64, which is 56% above median its own 10-year median of 12.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geratherm Medical AG stock overvalued right now?
Based on GuruFocus' analysis, Geratherm Medical AG (XTER:GME) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.13, compared to a current price of €2.53 — trading 19.2% below its estimated fair value. The current EV-to-EBITDA is 19.64, which is 56% above median its 10-year median of 12.61 and 29.6% above the Medical Devices & Instruments industry median of 15.16. Geratherm Medical AG's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Geratherm Medical AG (XTER:GME), the current EV-to-EBITDA is 19.64 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Geratherm Medical AG (XTER:GME) Overvalued in 2026?
Based on GuruFocus' analysis, Geratherm Medical AG stock appears to be undervalued.
The current stock price of €2.53 is trading 19.2% below its estimated GF Value™ of €3.13.
GuruFocus considers Geratherm Medical AG to be Modestly Undervalued.
Key valuation signals for XTER:GME:
EV-to-EBITDA: 19.64 (56% above median its 10-year median of 12.61)
GF Value™: €3.13 vs. price of €2.53 (19.2% below fair value)
Industry Position: 29.6% above the Medical Devices & Instruments median (#330 of 515)
No single metric tells the full story. See the XTER:GME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Geratherm Medical AG is a Germany-based medical technology company. The firm operates through four segments: Healthcare Diagnostic, Medical Warming Systems, Cardio/Stroke and Respiratory. Healthcare Diagnostic segment which generates majority revenue provides analog and digital products for measuring body temperature, blood pressure monitors and other products for measuring temperature, as well as related accessories. Medical Warming Systems offers solutions for temperature management at all stages in the pre-clinical and clinical care of the patients, such as rescue situations and operations. Cardio/Stroke segment comprises products for preventing strokes. The Respiratory segment focuses on the development and production of products for pulmonary functional diagnostics.
72GF Score
Get the complete analysis for XTER:GME
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:GME has been successfully added to your 
